FRNM · Freenome, Inc.

TXG

10x Genomics, Inc.

RBC's 2026-09-01 initiation at Sector Perform, $70, is the first published mark above Stephens' $65 of 2026-08-12 — and the shares closed $59.98 that session against $62.45 on 08-31, so the street's new high mark arrived without a bid. The Atera-plus-injunction re-rate is maturing, with the ~09-09 short-interest file the only dated input before the ~11-05 Q3 print.

BFLY

Butterfly Network, Inc.

Butterfly Embedded chip-licensing story got marquee validation — Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but the June double has stalled and news thinned; a binary Q2 print (~early Aug) is now the next input and the easy momentum leg is spent.

AVNS

Avanos Medical, Inc.

Closed record, not a pending trade: AIP's $25.00/share all-cash take-private completed 2026-07-27 (EV ~$1.272B), AVNS left the NYSE the same day, and the 2026-08-06 Form 15-12G — one holder of record — ended SEC reporting. No listed security and no catalyst inside 30 days; the only open per-share number is the DGCL §262 appraisal window, running 120 days from the 2026-07-27 effective date.

ABT

Abbott Laboratories

De-rating unwind is well advanced: $82.56 close on 2026-05-11 to $112.47 on 2026-08-28, with the ~$670M NEC settlement (2026-08-20) and Libre Duo's FDA De Novo authorization (2026-08-25) clearing two named overhangs. Price added almost nothing across both and RSI cooled 72.2 to 61.7, leaving a maturing narrative whose open question — the 6.5%–7.5% FY comparable guide against Q2's 4.8% — is untested until the ~mid-October Q3 print.